Related Experiment Video
Updated: Jun 19, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia
Rose Ann Padua1, Jerome Larghero, Marie Robin
1LBCH INSERM E0-03, U462 & U396, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, AP-HP 75010, Paris, France. rose.padua@kcl.ac.uk
Abstract:
Despite improved molecular characterization of malignancies and development of targeted therapies, acute leukemia is not curable and few patients survive more than 10 years after diagnosis. Recently, combinations of different therapeutic strategies (based on mechanisms of apoptosis, differentiation and cytotoxicity) have significantly increased survival. To further improve outcome, we studied the potential efficacy of boosting the patient's immune response using specific immunotherapy. In an animal model of acute promyelocytic leukemia, we developed a DNA-based vaccine by fusing the human promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) oncogene to tetanus fragment C (FrC) sequences. We show for the first time that a DNA vaccine specifically targeted to an oncoprotein can have a pronounced effect on survival, both alone and when combined with all-trans retinoic acid (ATRA). The survival advantage is concomitant with time-dependent antibody production and an increase in interferon-gamma (IFN-gamma). We also show that ATRA therapy on its own triggers an immune response in this model. When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia.
Insights
This study shows a novel DNA vaccine targeting the PML-RARA oncogene significantly improves survival in acute promyelocytic leukemia mouse models. Combining this immunotherapy with all-trans retinoic acid (ATRA) enhances protective immune responses against leukemia.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Acute leukemia remains difficult to cure, with limited long-term survival despite advances in targeted therapies.
- Improving patient outcomes necessitates exploring novel therapeutic strategies beyond current treatments.
- Specific immunotherapy offers a potential avenue to enhance the body's immune response against cancer cells.
Purpose of the Study:
- To investigate the efficacy of a DNA-based vaccine targeting the PML-RARA oncogene in an acute promyelocytic leukemia (APL) animal model.
- To evaluate the combined therapeutic effect of this DNA vaccine with all-trans retinoic acid (ATRA).
- To assess the impact of immunotherapy on survival rates and immune responses in APL.
Main Methods:
- Development of a DNA vaccine by fusing the human PML-RARA oncogene with tetanus fragment C (FrC).
- Administration of the DNA vaccine alone and in combination with ATRA in a mouse model of APL.
- Monitoring of survival rates, antibody production, and interferon-gamma (IFN-gamma) levels.
Main Results:
- The DNA vaccine targeting the PML-RARA oncoprotein demonstrated a significant survival advantage in the APL mouse model.
- Combination therapy with the DNA vaccine and ATRA further enhanced survival outcomes.
- Vaccination induced time-dependent antibody production and increased IFN-gamma levels, indicating an active immune response.
- ATRA therapy alone was also observed to trigger an immune response in this model.
Conclusions:
- A DNA vaccine targeting a specific oncoprotein can effectively improve survival in acute leukemia.
- Combining DNA vaccination with ATRA therapy generates robust immune responses against leukemia progression.
- This approach holds promise as a novel strategy to improve clinical outcomes for human leukemia patients.
